Non invasive neuromodulation device for enabling recovery of motor, sensory, autonomic, sexual, vasomotor and cognitive function
A neuromodulation system, device, and method are disclosed. In an embodiment, a neuromodulation method includes providing a neuromodulation system including a processor, a signal generator communicatively coupled to the processor, and at least one transcutaneous electrode communicatively coupled to the signal generator. The method also includes causing the at least one transcutaneous electrode to be applied a human patient having at least one dysfunctional spinal circuit. The method further includes facilitating transcutaneous electrical stimulation of the patient's spinal cord via the processor in cooperation with the signal generator causing activation of at least one spinal network (“SN”) to enable or improve voluntary movements of the patient's arms, trunk, and legs, or autonomic control of at least one of sexual activity, vasomotor activity, speech, swallowing, chewing, cardiovascular function, respiratory activity, body temperature, metabolic processes, or cognitive function.
1. A neuromodulation method comprising:
providing a neuromodulation system including:
a processor,
a signal generator communicatively coupled to the processor, and
at least one transcutaneous electrode communicatively coupled to the signal generator, the at least one transcutaneous electrode configured to be applied to a human patient having at least one dysfunctional spinal circuit;
facilitating transcutaneous electrical stimulation of the patient's spinal cord via the processor in cooperation with the signal generator using a first set of parameter values causing activation of at least one spinal network (“SN”) to enable or improve voluntary movements of the patient's arms, trunk, and legs, or autonomic control of at least one of sexual activity, vasomotor activity, speech, swallowing, chewing, respiratory activity, cardiovascular function, body temperature, metabolic processes, or cognitive function; and
repeating the facilitation of the transcutaneous electrical stimulation, via the processor and the signal generator, using different sets of parameter values by:
receiving data from at least one sensor in relation to the delivery of the transcutaneous electrical stimulation, wherein the at least one sensor includes at least one of a recording electrode, a recording electrode array, or a plurality of electrode arrays,
providing the first set of parameter values and the data to a server or a processing system for determining a second set of parameter values,
receiving the second set of parameter values from the server or the processing system, and
facilitating subsequent transcutaneous electrical stimulation, via the processor and the signal generator, using the second set of parameter values.
2. The method of claim 1 , wherein the autonomic control is one of cardiovascular function, body temperature control, or normalized metabolic processes in the patient having a neurologically derived paralysis.
3. The method of claim 1 , wherein the autonomic control includes at least one of bowel functions, bladder functions, or body temperature regulation.
4. The method of claim 1 , further comprising administering one or more neuropharmaceutical agent to the patient before or after the transcutaneous electrical stimulation is delivered.
5. The method of claim 4 , wherein the one or more neuropharmaceutical agent includes at least one of a serotonergic drug, a dopaminergic drug, a noradrenergic drug, a GABAergic drug, or a glycinergic drug.
6. The method of claim 1 , wherein the parameter values identify at least one of a waveform shape, an amplitude, a frequency, or a relative phasing of the transcutaneous electrical stimulation.
7. The method of claim 1 , wherein the at least one dysfunctional spinal circuit is due to a spinal cord injury (“SCI”) or a neurodegenerative brain injury associated with at least one of Parkinson's disease, Huntington's disease, Alzheimer's, dystonia, ischemia, stroke, amyotrophic lateral sclerosis (“ALS”), primary lateral sclerosis (“PLS”), or cerebral palsy.
8. A neuromodulation method comprising:
providing a neuromodulation system including:
a processor,
a signal generator communicatively coupled to the processor, and
at least one transcutaneous electrode communicatively coupled to the signal generator, the at least one transcutaneous electrode configured to be applied to a human patient having at least one dysfunctional spinal circuit;
facilitating transcutaneous electrical stimulation of the patient in a region of T11-T12 vertebrae via the processor in cooperation with the signal generator using a first set of parameter values causing activation of at least one spinal network (“SN”) to enable or improve voluntary movements of the patient's arms, trunk, and legs, or autonomic control of at least one of sexual activity, vasomotor activity, speech, swallowing, chewing, respiratory activity, cardiovascular function, body temperature, metabolic processes, or cognitive function; and
repeating the facilitation of the transcutaneous electrical stimulation, via the processor and the signal generator, using different sets of parameter values by:
receiving data from at least one sensor in relation to the delivery of the transcutaneous electrical stimulation, wherein the at least one sensor includes at least one of a recording electrode, a recording electrode array, or a plurality of electrode arrays,
providing the first set of parameter values and the data to a server or a processing system for determining a second set of parameter values,
receiving the second set of parameter values from the server or the processing system, and
facilitating subsequent transcutaneous electrical stimulation, via the processor and the signal generator, using the second set of parameter values.
9. The method of claim 8 , wherein the autonomic control is one of cardiovascular function, body temperature control, or normalized metabolic processes in the patient having a neurologically derived paralysis.
10. The method of claim 8 , wherein the autonomic control includes at least one of bowel functions, bladder functions, or body temperature regulation.
11. The method of claim 8 , further comprising administering one or more neuropharmaceutical agent to the patient before or after the transcutaneous electrical stimulation is delivered.
12. The method of claim 11 , wherein the one or more neuropharmaceutical agent includes at least one of a serotonergic drug, a dopaminergic drug, a noradrenergic drug, a GABAergic drug, or a glycinergic drug.
13. The method of claim 8 , wherein the parameter values identify at least one of a waveform shape, an amplitude, a frequency, or a relative phasing of the transcutaneous electrical stimulation.
14. The method of claim 8 , wherein the at least one dysfunctional spinal circuit is due to a spinal cord injury (“SCI”) or a neurodegenerative brain injury associated with at least one of Parkinson's disease, Huntington's disease, Alzheimer's, dystonia, ischemia, stroke, amyotrophic lateral sclerosis (“ALS”), primary lateral sclerosis (“PLS”), or cerebral palsy.
15. A neuromodulation system comprising:
a processor;
a signal generator communicatively coupled to the processor; and
at least one transcutaneous electrode communicatively coupled to the signal generator and configured for placement on a patient having at least one dysfunctional spinal circuit,
wherein the processor in cooperation with the signal generator is configured to:
apply, using a first set of parameter values, transcutaneous electrical stimulation to a patient's spinal cord causing activation of at least one spinal network (“SN”) to enable or improve voluntary movements of the patient's arms, trunk, and legs, or autonomic control of at least one of sexual activity, vasomotor activity, speech, swallowing, chewing, respiratory activity, cardiovascular function, body temperature, metabolic processes, or cognitive function,
repeat the application of the transcutaneous electrical stimulation using different sets of parameter values by:
receiving data from at least one sensor in relation to the delivery of the transcutaneous electrical stimulation, wherein the at least one sensor includes at least one of a recording electrode, a recording electrode array, or a plurality of electrode arrays,
providing the first set of parameter values and the data to a server or a processing system for determining a second set of parameter values,
receiving the second set of parameter values from the server or the processing system, and
applying subsequent transcutaneous electrical stimulation, via the processor and the signal generator, using the second set of parameter values.
16. The system of claim 15 , wherein the at least one dysfunctional spinal circuit is due to a spinal cord injury (“SCI”) or a neurodegenerative brain injury associated with at least one of Parkinson's disease, Huntington's disease, Alzheimer's, dystonia, ischemia, stroke, amyotrophic lateral sclerosis (“ALS”), primary lateral sclerosis (“PLS”), or cerebral palsy.
17. The system of claim 15 , wherein the parameter values identify at least one of a waveform shape, an amplitude, a frequency, or a relative phasing of the receptive first or second stimulation.
18. The system of claim 15 , further comprising causing one or more neuropharmaceutical agent to be administered to the patient.
19. The system of claim 18 , wherein the one or more neuropharmaceutical agent includes at least one of a serotonergic drug, a dopaminergic drug, a noradrenergic drug, a GABAergic drug, or a glycinergic drug.